论文部分内容阅读
生长抑素及其类似物奥曲肽能阻断许多肠道和胰腺肽的释放。有研究报道,奥曲肽300～1500μg/d,分2～3次皮下注射治疗类癌综合征有效。兰瑞肽是新近开发的生长抑素类似物,是聚丙交酯-聚乙交酯共聚体的微球体的缓释制剂,故可减少每天注射次数。本文对39例(男24例,女15例,平均63.7岁)不能切除的类癌综合征患者,给予兰瑞肽30mg,每2周1次肌注,共6个月,以评估其对类癌综合征的疗效和耐受性。
Somatostatin and its analogue octreotide block the release of many intestinal and pancreatic peptides. Studies have reported that octreotide 300 ~ 1500μg / d, 2 to 3 subcutaneous injection treatment of carcinoid syndrome is effective. Lanreotide is a recently developed somatostatin analogue, a sustained-release preparation of microspheres of polylactide-polyglycolide copolymer, which reduces the number of daily injections. In this paper, 39 patients (24 males and 15 females, average age 63.7 years) with unresectable carcinoid syndrome were treated with lanreotide 30 mg and intramuscularly every 2 weeks for a total of 6 months to assess their The efficacy and tolerability of cancer syndrome.